首页> 美国卫生研究院文献>AAPS PharmSci >A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms
【2h】

A Report from the Pediatric Formulations Task Force: Perspectives on the State of Child-Friendly Oral Dosage Forms

机译:儿科配方工作组的报告:对儿童友好的口服剂量形式的状态的观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Despite the fact that a significant percentage of the population is unable to swallow tablets and capsules, these dosage forms continue to be the default standard. These oral formulations fail many patients, especially children, because of large tablet or capsule size, poor palatability, and lack of correct dosage strength. The clinical result is often lack of adherence and therapeutic failure. The American Association of Pharmaceutical Scientists formed a Pediatric Formulations Task Force, consisting of members with various areas of expertise including pediatrics, formulation development, clinical pharmacology, and regulatory science, in order to identify pediatric, manufacturing, and regulatory issues and areas of needed research and regulatory guidance. Dosage form and palatability standards for all pediatric ages, relative bioavailability requirements, and small batch manufacturing capabilities and creation of a viable economic model were identified as particular needs. This assessment is considered an important first step for a task force seeking creative approaches to providing more appropriate oral formulations for children.
机译:尽管有很大一部分人口无法吞咽片剂和胶囊剂,但这些剂型仍然是默认标准。由于较大的片剂或胶囊大小,适口性差和缺乏正确的剂量强度,这些口服制剂使许多患者,特别是儿童无法接受。临床结果通常是缺乏依从性和治疗失败。美国药物科学家协会成立了儿科制剂工作组,由具有各种专业领域的成员组成,包括儿科,制剂开发,临床药理学和监管科学,以便确定儿科,制造和监管问题以及需要研究的领域和法规指导。所有儿童年龄的剂型和适口性标准,相对生物利用度要求,小批量生产能力以及建立可行的经济模型被确定为特殊需求。该评估被认为是工作队寻求创新方法为儿童提供更合适的口服制剂的重要的第一步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号